PTEN is by now one of, if not the most, frequently mutated, deleted and silenced tumor suppressor in the history of cancer genetics. Through its ability to dephosphorylate 3 0 of phosphatidylinositol 3-5-trisphosphate, PTEN undoubtedly functions to restrict the activation of a fundamental proto-oncogenic signaling pathway triggered and initiated by phosphoinositide 3 kinase (PI3K). The PTEN/PI3K pathway is of critical relevance to human cancer not only because it's so frequently implicated in human tumorigenesis, but also because many of the important hubs in this pathway, including PTEN itself, are amenable to pharmacological manipulation with numerous agents and several small molecule inhibitors. Thus, the exquisite 'drugability' of this pathway in turn, provides great hope that its modulation may be decisive in tackling cancer and other diseases with targeted molecules and their combinations.
If this was not exciting and timely enough, the PTEN field has recently taken a further unexpected leap, in part, thought the realization that PTEN may exert critical nuclear functions, which are likely independent of its phosphatidylinositol 3-5-trisphosphate phosphatase activity. Moreover, these new functions are subject to a tremendously complex layer of post-transcriptional and post-translational regulation.
Although there is no doubt that PTEN function in disease is predominantly impacted by genetic events compromising the PTEN locus, numerous factors regulating PTEN transcription as well as post-transcriptional-modifiers (such as PTEN-targeting miRNAs) and post-translational regulators have been recently identified. As expected for an important tumor suppressor, PTEN is dynamically modified at multiple levels, for instance PTEN is acetylated, phosphorylated and ubiquitinylated and certainly, additional PTEN modifications will be characterized in due course.
Ubiquitinylation of PTEN has been shown to be essential for its ability to accumulate in the nucleus, and these critical lysines are subject to mutation-associated aberrant nuclear exclusion of PTEN and cancer susceptibility in humans. Furthermore, PTEN contains two so-called PEST motifs, characteristic of short-lived proteins that are subject to ubiquitin-mediated proteasome degradation. Paradoxically, PTEN is generally a long-lived and stable protein in normal cells; however, aberrant degradation of PTEN could play an important role under pathological circumstances. On this basis, the identification of PTEN-targeting E3-ligases and deubiquitinating enzymes (DUBs) would be of tremendous interest because these enzymes may in turn serve as targets for the development of novel cancer therapeutics. To date, NEDD4-1 is the only described E3-ligase to ubiquitinylate PTEN, as identified in an unbiased screen for PTEN poliubiquitinylation. However, NEDD4-1 is not the only E3-ligase for PTEN (as will soon be reported), but the ability of this protein to bind and ubiquitinylate PTEN is consistent with recent reports from three independent groups. In contrast, through the examination of NEDD4-1 complete knock out cells from a mouse embryo, a recent manuscript has concluded that this E3-ligase is dispensable for PTEN localization and levels. As most of the reported data are derived from a germ line and not acute NEDD4-1 deletion, the likelihood that cells from the developing embryo might adapt and compensate for the lack of NEDD4-1 through the activation of additional PTEN E3-ligases is high. However, the same group also reports that NEDD4-1 is unable to bind and ubiquitinylate PTEN. These findings that are very puzzling in light of three recent independent reports concluding just the opposite. This exhilarating controversy highlights the requirement of further studies aimed at analyzing the conditions where PTEN E3s and/or DUBs are in action and how and when their activity is specifically directed to PTEN in both physiological and pathophysiological circumstances.
Through the study of its complex regulation PTEN itself may become a subject of therapeutic intervention in the near future. In the meantime, intricate knowledge of the PI3K-AKT-TOR signaling pathway that PTEN regulates, as well as of the numerous novel signaling cross talks and feedback loops in action, is already proving extremely useful in driving the development of tailored targeted combinatorial therapeutic interventions with pathway modulators already or very soon to be in clinical trials. These exciting themes will constitute the focus of this issue of reviews dedicated to PTEN and its associated pathways.
